API
< Back to situations

This situation has concluded

It was preserved as a record on September 4; the timeline below shows how it unfolded, with sources. Get the briefing to follow the top situations still developing: three emails a week, sourced and in order.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 22 sources · 8 days · First seen · Last updated

Eli Lilly Q2 2026 earnings and revenue surge

Overview

Eli Lilly’s shares rose modestly on July 28, 2026 after analysts lifted price targets ahead of its earnings release. The company posted Q2 2026 non‑GAAP earnings of $8.38 per share, well above the $6.07 consensus, and revenue of about $23 billion – a 48 % year‑over‑year increase driven by its obesity‑treatment portfolio. Sales of the diabetes drug Mounjaro jumped 91 % to $9.9 billion and the weight‑loss drug Zepbound grew 44 % to $4.9 billion, together accounting for roughly two‑thirds of quarterly revenue. Worldwide realized prices for the GLP‑1 medicines fell 13 % (3 % in the United States, 36 % outside) after Mounjaro entered China’s national reimbursement list. Adjusted net income rose 32 % to $7.5 billion, prompting Lilly to raise its full‑year 2026 revenue outlook to $85‑$87 billion and reaffirm its EPS target. In the same quarter Lilly launched an oral obesity pill, Foundayo, which generated $98 million in sales, short of the $105.6 million analysts had expected.

Entities

Eli Lilly and Company · Excelsior Advisor Network LLC · China National Reimbursement Drug List · Tilray Brands · UGI Corporation

Claims

What the coverage asserts, and how many sources carry each claim.

Timeline

  1. [BUSINESS] 20 sources
    Eli Lilly Q2 Revenue Jumps 48% on Obesity Drug Sales

    Eli Lilly’s Q2 revenue hit $23 billion, up 48%, led by Mounjaro ($9.9 bn) and Zepbound ($4.9 bn); obesity drugs now make up about two‑thirds of sales, prices fell 13% globally, and the full‑year outlook was nud

  2. [BUSINESS] 4 sources
    Eli Lilly shares rise 2.1% on analyst upgrades; MercadoLibre to report Q2 2026 earnings; Elicio Therapeutics forecasts a

    Eli Lilly shares rose 2.1% as analysts lifted price targets; MercadoLibre will release Q2 2026 results on Aug 5; Elicio Therapeutics forecasts a Q2 2026 loss of $0.53 per share.

Sources

aijourn.com · bygumbygolly.com · elceo.com · finbold.com · gazeta.eu · heartofdublin.com · last10k.com · lesaffaires.com · lesinguliersete.fr · levisonenterprises.com · lopinion.fr · mommygearest.com · moneytimes.com.br · news.alphastreet.com · otravel.com · pharmexec.com · seekingalpha.com · seucreditodigital.com.br · shippingherald.com · stocknews.com · tekedia.com · valor.globo.com

This summary has been updated 5 times: see revision history